Landscape Capital Management L.L.C. Has $1 Million Stake in Glaukos Corporation $GKOS

Key Points

• Landscape Capital Management L.L.C. increased its stake in Glaukos Corporation by 231.2% in the first quarter, acquiring an additional 7,109 shares, bringing its total holdings to 10,184 shares worth approximately $1,002,000.
• Several other institutional investors have also significantly increased their positions in Glaukos, with increases ranging from 133.9% to 3,957.1% during the same period.
• Glaukos' stock has a current price of $95.86 with a market capitalization of $5.50 billion, while analysts have set an average price target of $127.42 for the company.

Landscape Capital Management L.L.C. increased its stake in Glaukos Corporation (NYSE:GKOS - Free Report) by 231.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,184 shares of the medical instruments supplier's stock after purchasing an additional 7,109 shares during the period. Landscape Capital Management L.L.C.'s holdings in Glaukos were worth $1,002,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Bessemer Group Inc. lifted its position in Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier's stock worth $27,000 after buying an additional 158 shares in the last quarter. Whipplewood Advisors LLC boosted its stake in shares of Glaukos by 3,957.1% during the 1st quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 277 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in shares of Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier's stock worth $37,000 after buying an additional 159 shares during the last quarter. Versant Capital Management Inc boosted its stake in shares of Glaukos by 583.9% during the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after buying an additional 327 shares during the last quarter. Finally, CoreCap Advisors LLC boosted its stake in shares of Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after buying an additional 200 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Wells Fargo & Company boosted their price objective on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Zacks Research lowered shares of Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. BTIG Research restated a "buy" rating on shares of Glaukos in a research note on Monday, July 14th. Mizuho set a $130.00 price objective on shares of Glaukos in a research note on Thursday, July 31st. Finally, UBS Group boosted their price objective on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $127.42.

Glaukos Stock Performance

Glaukos stock traded down $4.22 during trading hours on Thursday, hitting $90.25. The company had a trading volume of 1,169,166 shares, compared to its average volume of 667,519. The firm has a market cap of $5.18 billion, a PE ratio of -54.69 and a beta of 0.77. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. Glaukos Corporation has a one year low of $77.10 and a one year high of $163.71. The firm has a 50-day moving average of $95.16 and a 200 day moving average of $97.95.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.02. The firm had revenue of $124.12 million for the quarter, compared to analysts' expectations of $115.49 million. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business's revenue was up 29.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.52) EPS. Glaukos has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.